Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00610571 · ClinicalTrials.gov registry record · Phase 1
Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas
A Phase 1 study of Glioblastoma and Gliosarcoma, sponsored by Katy Peters.
- Completed
- Registry status
- Phase 1
- Development phase
- 62
- Enrollment target
- 1
- Study location
NCT00610571: Completed Phase 1 study of Glioblastoma and Gliosarcoma, sponsored by Katy Peters.
NCT00610571 is a Phase 1 study of Glioblastoma and Gliosarcoma that has completed, run by Katy Peters. The registered enrollment target is 62 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (43% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00610571, a Phase 1 study of Glioblastoma and Gliosarcoma, has completed, sponsored by Katy Peters.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 62 participants
- Enrollment target
- 1
- Study location
Study Summary
Objectives: * To determine the maximum tolerated dose of oral topotecan when administered with Temodar to patients with malignant glioma * To characterize any toxicity associated with the combination oral topotecan and Temodar. * To observe patients for clinical antitumor response when treated with oral topotecan and Temodar.
Conditions Studied
Interventions
- DRUG Oral Topotecan and Temodar
Study Locations (1)
North Carolina
- Duke University Health System - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2004-04 |
| Est. Completion | 2012-04 |
| Phase | Phase 1 |
What the finished NCT00610571 record still lists
NCT00610571 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 62 participants, a relatively small participant target, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (43% lower).
The record links to 3 conditions, with Glioblastoma appearing as the primary indexed condition, and to 1 intervention - of which Oral Topotecan and Temodar is the first listed.
NCT00610571 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT00610571 about?
NCT00610571 is a clinical study titled "Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas". Objectives: * To determine the maximum tolerated dose of oral topotecan when administered with Temodar to patients with malignant glioma * To characterize any toxicity associated with the combination oral topotecan and Temodar. * To observe patients for clinical antitumor response when treated with...
What is the current status of trial NCT00610571?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 62 participants. The study started on 2004-04. Estimated completion is 2012-04.
What conditions does trial NCT00610571 study?
This clinical trial studies the following conditions: Glioblastoma, Gliosarcoma, Anaplastic Astrocytoma.
What interventions are being tested in trial NCT00610571?
The interventions under investigation include: Oral Topotecan and Temodar (DRUG).
Who is sponsoring clinical trial NCT00610571?
This trial is sponsored by Katy Peters, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00610571 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00610571's enrollment target sits among peer trials
62 71st of 199 higher than 127 of 199 other Glioblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
RECRUITING · Phase 1
-
A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma
RECRUITING · Phase 1
-
CARv3-TEAM-E T Cells in Glioblastoma
RECRUITING · Phase 1
-
CUE-102 in Recurrent Glioblastoma
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03231150 · 62 participants · NA
Plantar Fasciitis Randomized Clinical Control Trial
- NCT03458676 · 62 participants · NA
Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies
- NCT03596086 · 62 participants · Phase 1
HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
- NCT03904498 · 62 participants · Phase 2
COMT Inhibition Among Individuals With Comorbid AUD/ADHD
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia